Colostrinin™
ReGen Therapeutics Plc was formed in February 1998 to develop Colostrinin™, a proline-rich polypeptide complex derived from mammalian colostrum. The complex and the peptides within it are viewed as having potential utility in neurodegenerative illnesses such as Alzheimer’s disease, Parkinson’s Disease, Multiple Sclerosis and Amyotrophic Lateral Sclerosis.
Colostrinin™ was originally identified by scientists working in Poland, where early clinical studies, dating back to 1995, had indicated a significant potential benefit to Alzheimer’s disease sufferers. ReGen therefore conducted a placebo-controlled clinical trial of it’s own on Alzheimer’s sufferers in Poland, which completed in mid-2002. Results from the trial showed 33% of patients achieved stabilisation or improvement in their disease condition after 30 weeks of treatment, with efficacy demonstrated in both mild and moderate symptom groups. A good safety profile and no Serious Adverse Events or other safety concerns were observed. An article reviewing the results of this trial was published in the February 2004 issue of the Journal of Alzheimer’s Disease.
Since 2003 ReGen has been investigating the possibility of developing a nutraceutical version of Colostrinin™. The natural origin and nature of Colostrinin™ means that it conforms to the general criteria for non-pharmaceutical health supplements, so the Company formulated a nutraceutical development plan which has run in parallel with the continuing development of pharmaceutical drug-candidates based on the constituent peptides of the Colostrinin™ complex. ReGen has filed a substantial number of patent applications with various patent authorities throughout the World. These patents are targeted at protecting both discoveries in the field of the treatment of Alzheimer’s disease and at wider applications for Colostrinin™ and its constituent peptides in other neurodegenerative disease areas. Most of ReGen’s patent applications are still in the process of examination by the various national patent authorities, but up to September 2007, the Company has had its main “use” patent on Colostrinin™ granted in the United Kingdom, USA, Australia, New Zealand, Russia, China, Turkey, Israel, South Korea, Czech Republic and South Africa and another three patents (under licence from University of Texas Medical Branch) granted in the USA. ReGen’s subsidiary, ReGen Biotech Ltd had a patent on the use of Colostrinin™ in combination with other materials as a dietary supplement, granted in the UK in October 2002.
Last updated January 2008
